This course has expired. You can still review the content but course credit is no longer available.
This course is designed to educate ophthalmologists about new and emerging pharmacological treatments for pre-cataract presbyopic patients. This course will focus on the unique psychology of the pre-cataract presbyopia patient, details on evolving treatment options, and faculty will offer pearls for identifying candidates and mastering conversations with these patients throughout their journey.
Supported by unrestricted education grants from Alcon, Johnson & Johnson Vision, and Orasis Pharmaceuticals.
Upon completion of this activity, the participant should be able to:
a. Define the ideal pre-cataract presbyopia patient for pharmacological treatment, including prevalence, age ranges, refractive error levels, key demographics, and other clinical and socioeconomic parameters
b. Determine ideal practices for identifying and diagnosing pre-cataract presbyopic patients
c. Compare and contrast the advantages and disadvantages of the various mechanisms of action for different pharmacological presbyopia treatments, including efficacy, safety, and functionality
d. Describe ideal practice protocols for treating pre-cataract presbyopia patients with medical therapies
Provided by Evolve Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education, LLC, and The Fundingsland Group. Evolve Medical Education, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Evolve Medical Education, LLC designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Recommended internet speed 5Mbps+
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Marjan Farid, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Bio-Tissue, Carl Zeiss Meditec, Corneagen, Dompe, Eyepoint, Eyevance, Johnson & Johnson Vision, Kala, and Novartis.
Nicole R. Fram, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan, CorneaGen, Johnson & Johnson Vision, and Ocular Therapeutics. Grant/Research Support: Alcon, and Allergan. Speaker’s Bureau: Alcon, BVI, CorneaGen, Dompe, MST, and Ocular Therapeutix. Stock/Shareholder: CorneaGen, and Ocular Science.
Edward J. Holland, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Abingworth, Aerie Pharmaceuticals, Akros Pharma, Inc., Alcon, Aldeyra Therapeutics, Allegro, Allergan, Azura Ophthalmics, BlephEx, LLC, BRIM biotech, Claris Bio, Corneat, CorneaGen, Expert Opinion, Dompe, EyePoint, Glaukos Corporation, Hanall, Invirsa, Kala Pharmaceuticals, Mati Therapeutics, Merck KGgA, Novartis NIBR, Novartis Pharmaceuticals, Ocular Therapeutix, Ocuphire, Omeros Corporation, OysterPoint, Precise Bio, Prometic Biotherapeutics, ReGentree, LLC, Retear, Senju, Shire, Sight Sciences, Slack, Inc., Tarsus RX, TearLab Research, Inc., Vomaris, W.L. Gore and Associates, and Zeiss. Speakers Bureau: Alcon, Novartis Pharmaceticals, Omeros Corporation, Senju, and Shire. Other Financial Support: Alcon, Mati Therapeutics, Novartis Pharmaceuticals, Omeros Corporation, Senju, and Shire.
The Evolve Medical Education and The Fundingsland Group staff and planners have no financial relationships with commercial interests.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group, or Alcon, Johnson & Johnson Vision, and Orasis Pharmaceuticals.